{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:53:39Z","timestamp":1764996819280},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,3,8]],"date-time":"2007-03-08T00:00:00Z","timestamp":1173312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2007,4,2]]},"DOI":"10.1007\/s00228-007-0282-8","type":"journal-article","created":{"date-parts":[[2007,3,7]],"date-time":"2007-03-07T03:25:12Z","timestamp":1173237912000},"page":"479-483","source":"Crossref","is-referenced-by-count":17,"title":["Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients"],"prefix":"10.1007","volume":"63","author":[{"given":"Somchai","family":"Sriwiriyajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werawath","family":"Mahatthanatrakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wibool","family":"Ridtitid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sutep","family":"Jaruratanasirikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,3,8]]},"reference":[{"key":"282_CR1","unstructured":"Department of Health and Human Services (2006) Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents-October 10, 2006. http:\/\/www.aidsinfo.nih.gov . Assessed December 20, 2006"},{"key":"282_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198223010-00001","volume":"23","author":"RC Heel","year":"1982","unstructured":"Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS (1982) Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23:1\u201336","journal-title":"Drugs"},{"key":"282_CR3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00003495-199856060-00014","volume":"56","author":"JC Adkins","year":"1998","unstructured":"Adkins JC, Noble S (1998) Efavirenz. Drugs 56:1055\u20131064","journal-title":"Drugs"},{"key":"282_CR4","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0378-4347(98)00253-9","volume":"715","author":"KH Yuen","year":"1998","unstructured":"Yuen KH, Peh KK (1998) Simple high-performance liquid chromatographic method for determination of ketoconazole in human ploasma. J Chromatogr B 715:436\u2013440","journal-title":"J Chromatogr B"},{"key":"282_CR5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/10454411000110020301","volume":"11","author":"AN Ellepola","year":"2000","unstructured":"Ellepola AN, Samaranayake LP (2000) Oral candidal infections and antimycotics. Crit Rev Oral Biol Med 11:172\u2013198","journal-title":"Crit Rev Oral Biol Med"},{"key":"282_CR6","unstructured":"Thai Ministry of Public Health (2002) National guidelines for the clinical management of HIV infection in children and adults, 7th edn. Garnsadsana, Bangkok"},{"key":"282_CR7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1034\/j.1600-0714.2000.290501.x","volume":"29","author":"R Teanpaisan","year":"2000","unstructured":"Teanpaisan R, Nittayananta W, Chongsuvivatwong V (2000) Biotypes of oral Candida albicans isolated from AIDS patients and HIV-free subjects in Thailand. J Oral Pathol Med 29:193\u2013199","journal-title":"J Oral Pathol Med"},{"key":"282_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00126334-200402010-00007","volume":"35","author":"J Roey Van","year":"2004","unstructured":"Van Roey J, Haxaire M, Kamya M, Lwanga I, Katabira E (2004) Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 35:144\u2013150","journal-title":"J Acquir Immune Defic Syndr"},{"key":"282_CR9","first-page":"177","volume":"1","author":"EW Gascoigne","year":"1981","unstructured":"Gascoigne EW, Barton GJ, Michaels M, Meuldermans WH (1981) The kinetics of ketoconazole in animals and man. Clin Res Rev 1:177\u2013187","journal-title":"Clin Res Rev"},{"key":"282_CR10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1128\/AAC.21.1.151","volume":"21","author":"C Brass","year":"1982","unstructured":"Brass C, Galgiani JN, Blaschke TF, Defelice R, O\u2019Reilly RA, Stevens DA (1982) Disposition of ketoconazole, an oral antifungal, in human. Antimicrob Agents Chemother 21:151\u2013158","journal-title":"Antimicrob Agents Chemother"},{"key":"282_CR11","unstructured":"Lamson M, Robinson P, Gigliotti M, Myers WM (1998) The pharmacokinetic interaction of nevirapine and ketoconazole. In: Abstr 12th World AIDS Conf, abstr 12218. Geneva, p 55"},{"key":"282_CR12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00003088-199936040-00004","volume":"36","author":"M Berry","year":"1999","unstructured":"Berry M, Mulcahy F, Merry C, Gibbons S, Back D (1999) Pharmacokinetics and potential interactions and amongst antiretroviral agents used to treat HIV infection. Clin Pharmacokinet 36:289\u2013304","journal-title":"Clin Pharmacokinet"},{"key":"282_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2125.2001.00342.x","volume":"51","author":"SM Clarke","year":"2001","unstructured":"Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbon SE, Berry MG, Back DJ (2001) The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 51:213\u2013217","journal-title":"Br J Clin Pharmacol"},{"key":"282_CR14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1067\/mcp.2002.121424","volume":"71","author":"RE Aarnoutse","year":"2002","unstructured":"Aarnoutse RE, Grintjes K, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM (2002) The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 71:57\u201367","journal-title":"Clin Pharmacol Ther"},{"key":"282_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2125.2005.02369.x","volume":"60","author":"E Dailly","year":"2005","unstructured":"Dailly E, Allavena C, Raffi F, Jolliet P (2005) Pharmacokinetic evidence of the induction of lopinavir metabolism by efavirenz. Br J Clin Pharmacol 60:32\u201334","journal-title":"Br J Clin Pharmacol"},{"key":"282_CR16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.qai.0000167156.44980.33","volume":"39","author":"JG Gerber","year":"2005","unstructured":"Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA (2005) Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 39:307\u2013312","journal-title":"J Acquir Immune Defic Syndr"},{"key":"282_CR17","first-page":"226","volume":"8","author":"N Berruet","year":"2005","unstructured":"Berruet N, Sentenac S, Auchere D, Gimenez F, Farinotti R, Fernandez C (2005) Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J Pharm Pharmaceut Sci 8:226\u2013234","journal-title":"J Pharm Pharmaceut Sci"},{"key":"282_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2002.124519","volume":"72","author":"S Mouly","year":"2002","unstructured":"Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkin PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in human. Clin Pharmacol Ther 72:1\u20139","journal-title":"Clin Pharmacol Ther"},{"key":"282_CR19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","volume":"46","author":"EJ Wang","year":"2002","unstructured":"Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW (2002) Interaction of Common Azole Antifungals with P-glycoprotein. Antimicrob Agents Chemother 46:160\u2013165","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-007-0282-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0282-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:51:38Z","timestamp":1558687898000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-007-0282-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,8]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,4,2]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1007\/s00228-007-0282-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,8]]}}}